Novo’s end-stage hypertension trial drug fails, $817m impairment loss
Novo Nordisk’s end-stage trial for hypertension drug has failed to meet its primary goal and the Danish multinational has recognised an impairment loss.
Drugs
Health
Pharma
Drugs
Health
Pharma
Teva to sell generic version of Novo Nordisk’s diabetic drug in US
Israel’s Teva Pharmaceuticals will start selling a generic version of Novo Nordisk’s type 2 diabetic drug Victoza in the US market.
Drugs
Health
Pharma
Novo Nordisk to set up $4.1 billion injectables facility in US’s North Carolina
Novo Nordisk, a Danish pharmaceutical multinational, will invest $4.1 billion to build a new factory in the US to make obesity and chronic.
Drugs
Health
Pharma
WHO issues medical alert on falsified weight-loss, diabetic drugs
The World Health Organization has issued a medical product alert on falsified semaglutides, an active ingredient in Ozempic, a diabetic drug made by.
Drugs
Health
Pharma
FDA panel rejects Novo Nordisk’s weekly jab to treat type 1 diabetes
The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA refused approval for a once-weekly jab to control blood sugar levels in people.
Drugs
Health
Pharma
Novo Nordisk raises sales forecast on strong demand for anti-obesity drug
HQ Team May 2, 2024: Novo Nordisk, Europe’s most valuable company, has raised its 2024 revenue outlook on the back of its popular.
Drugs
Health
Pharma
Viking Therapeutics’ weight-loss drug shows ‘positive’ results in early trials
US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.
Drugs
Health
Pharma
Novo to buy Cardior for $1.1b to expand cardiovascular segment
HQ Team March 25, 2024: Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises.
Drugs
Health
Pharma
Novo Nordisk unveils new drug to fight obesity, says 13% effective
HQ Team March 11, 2024: Danish drugmaker Novo Nordisk’s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company.
Drugs
Health
Pharma
Novo Nordisk says Ozempic reduces kidney disease progression
HQ Team March 6, 2024: Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney death in 24%.